Loading...

Solving coronavirus together

Invest in the world’s first independent coronavirus vaccine and antibody treatment.


STAY UPDATED

Thank you. We'll stay in touch.

What is Covidax

COVIDAX is a historically unique opportunity to invest in a sector that is otherwise restricted to few big pharma corporations and large investment funds. COVID-19 destroyed millions of lifes and broke the world economy. We are one of the very few truly independent scientific teams with sufficient expertise and resources to develop our own COVID-19 program - a vaccine (ACvac1) and an antibody treatment (ACmab1). In the global race for a vaccine, this is unique. You can invest right from this website and become a shareholder in AXON COVIDAX, a.s.. Help us bring the cure to all people in need, independently of all the political and corporate pressure, and get a share of the future profit.


Let’s build a world where people take matters into their own hands

About us


We are a private biotech company independent of big pharmaceutical industry. Building on 21 years of research in Alzheimer’s disease, initiated by Prof. Novak’s team after his discovery of key pathological changes of tau proteins at Laboratory of Molecular Biology, MRC, Cambridge, UK in 1988, we are now putting our proprietary technology to use to develop our own vaccine and antibody treatment against COVID-19.

Product Pipeline


There is a global race for a cure against COVID-19. We have developed two alternative solutions to fight the global pandemic.

Our vaccine ACvac1 is unique because it contains only functionally important pieces of the target viral protein, thus limiting negative side-effects after treatment and stimulating the immune system. In comparison to other vaccine candidates, our solution is tailored to elderly population and people with immunodeficiencies, who are especially vulnerable to the COVID-19.

Our monoclonal antibody ACmab1 is a laboratory-made protein that mimics the immune system’s ability to fight off the virus SARS-CoV-2. ACmab1 demonstrated the ability to completely neutralize the live virus in first trials.

Clinical trials


Using our previous technology platform, we can get to clinical trials and ultimately the product approvals much more effectively and in a much shorter time. We want to stay independent and open the project to people for investment. Support us now and be part of the first independent COVID-19 programme in the world.

Product pipeline

ACvac1
Peptide Vaccine against COVID-19
ACmab1
Antibody Treatment against COVID-19





DISCOVER OUR STORY

Taken from Axon lab



GLOBAL IMPACT OF COVID-19

CASES (Worldwide)

0.0 Million

(2,587,225 Deaths) Source: WHO

UNEMPLOYMENT (G7 countries)

0.0 Million

(+72% vs Jan20)
Source: OECD

CANCELED FLIGHTS (Rev. loss)

$0 Billion

(-51% seats) Source: ICAO

Timeline

  • 1988

    Discovery of tau proteins in Alzheimer's disease

    Discovery of tau proteins by Prof. Novak in a team of Nobel Prize laureates at MRC Cambridge.

  • 1999

    AXON Neuroscience

    Prof. Novak co-founded AXON Neuroscience to use his groundbreaking discovery in the research of Alzheimer‘s disease.

  • 2013

    Tau vaccine AADvac1

    The first tau vaccine AADvac1 entered into the clinical trials

  • 2019

    Successful Phase II

    Positive phase II results with the world's first Tau Vaccine for Alzheimer's Disease - AADvac1

  • March 2020

    Vaccine development

    First exploratory use of Axon’s vaccine platform to develop a vaccine against COVID-19.

  • April - September 2020

    Pre-clinical trials

    Patent and pre-clinical trials

  • November 2020

    Open project to public investors

    Investors can begin investing in the project from this website.

  • November/December 2020

    Discovery of a new potential therapy ACmab1 against COVID-19

    Public announcement of a new potential antibody therapy ACmab1 against COVID-19 showing strong ability to completely neutralize the virus SARS-CoV-2.

  • Quarter 1 2021

    First-in-human clinical trials

    First-in-human clinical trials (planned).

Press releases

DOCUMENTS

CONTACT US


Send us an email or call and we will be happy to talk some more.

STAY UPDATED

By using the website, you consent to our use of cookies in accordance with the terms of this policy.